Streetbeat News

Price Targets

IMVT

Immunovant (NASDAQ:IMVT) has received positive analyst ratings in the last quarter, with 7 bullish and 6 somewhat bullish ratings out of 13 total, and no indifferent or bearish ratings. The average price target is $43.69, representing an implied upside from the current price of $39.13. This target has increased by 36.53% from the previous target of $32.00. Analysts use various data sources to provide these ratings, which are opinions and can vary in accuracy.

Portfolio Pulse from Benzinga Insights

December 01, 2023 | 8:00 pm

CBRL

Over the past 3 months, 8 Wall Street analysts have provided ratings for Cracker Barrel Old (NASDAQ:CBRL) with an average price target of $79.62, representing an upside from the current price of $67.56. The consensus includes 1 bullish, 5 indifferent, and 2 bearish stances. The current average price target has decreased by 13.46% from the previous target of $92.00. Analysts typically review stocks quarterly and may provide forecasts on growth, earnings, and revenue, but their advice can be subject to error.

Portfolio Pulse from Benzinga Insights

December 01, 2023 | 8:00 pm

CRC

Over the past 3 months, 5 analysts have provided ratings for California Resources (NYSE:CRC), with 4 being bullish and 1 somewhat bullish. There have been no bearish or indifferent ratings. The average price target is $65.2, representing an upside from the current price of $51.21, but this is a decrease from the previous average price target of $66.00.

Portfolio Pulse from Benzinga Insights

December 01, 2023 | 8:00 pm

ONB

Old National Bancorp's stock (ONB) is trading higher following Citigroup's initiation of coverage with a Buy rating and a price target of $17.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 7:58 pm

BIG

Piper Sandler analyst Peter J. Keith maintained an Underweight rating on Big Lots, Inc. (NYSE:BIG) and lowered the price target from $6.00 to $3.50. Big Lots reported a 14.7% year-on-year sales decline in Q3 FY23, missing estimates. Keith anticipates continued comparable sales challenges in 2024, expecting negative EBITDA and cash burn. Despite cost-cutting efforts, including a $300 million reduction, and inventory management, Keith warns that increased closeout buys could lead to higher inventory and working capital commitments. He forecasts FY23 revenues of $4.725 billion with an EPS loss of $(11.05). BIG shares rose 19.45% to $6.30 on the last check Friday.

Portfolio Pulse from Nabaparna Bhattacharya

December 01, 2023 | 7:55 pm

EWBC

East West Bancorp's stock (EWBC) is trading higher following Citigroup's initiation of coverage with a Buy rating and a $75 price target.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 7:52 pm

OZK

Bank OZK's stock is experiencing an uptick following Citigroup's initiation of coverage with a Buy rating and a price target of $50.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 7:51 pm

CC

Chemours shares have risen following an upgrade by RBC Capital from Sector Perform to Outperform, with a price target increase from $28 to $40.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 7:48 pm

MRNA

JP Morgan analyst Jessica Fye has maintained a Neutral rating on Moderna (NASDAQ:MRNA) but has reduced the price target from $93 to $90.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 7:41 pm

KR

JP Morgan analyst Ken Goldman has maintained an Overweight rating on Kroger (NYSE:KR) but has reduced the price target from $54 to $53.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 7:38 pm